title: Synthesis, biological evaluation, X-ray structure, and pharmacokinetics of aminopyrimidine c-jun-N-terminal kinase (JNK) inhibitors.
abstract: Given the significant body of data supporting an essential role for c-jun-N-terminal kinase (JNK) in neurodegenerative disorders, we set out to develop highly selective JNK inhibitors with good cell potency and good brain penetration properties. The structure-activity relationships (SAR) around a series of aminopyrimidines were evaluated utilizing biochemical and cell-based assays to measure JNK inhibition and brain penetration in mice. Microsomal stability in three species, P450 inhibition, inhibition of generation of reactive oxygen species (ROS), and pharmacokinetics in rats were also measured. Compounds 9g, 9i, 9j, and 9l had greater than 135-fold selectivity over p38, and cell-based IC(50) values < 100 nM. Moreover, compound 9l showed an IC(50) = 0.8 nM for inhibition of ROS and had good pharmacokinetic properties in rats along with a brain-to-plasma ratio of 0.75. These results suggest that biaryl substituted aminopyrimidines represented by compound 9l may serve as the first small molecule inhibitors to test efficacy of JNK inhibitors in neurodegenerative disorders.
authors: Department of Molecular Therapeutics, and Translational Research Institute, The Scripps Research Institute, Scripps Florida, 130 Scripps Way A2A, Jupiter, Florida 33458, USA.
authors: Ted
authors: T
authors: Kamenecka
authors: Rong
authors: R
authors: Jiang
authors: Xinyi
authors: X
authors: Song
authors: Derek
authors: D
authors: Duckett
authors: Weimin
authors: W
authors: Chen
authors: Yuan Yuan
authors: YY
authors: Ling
authors: Jeff
authors: J
authors: Habel
authors: John D
authors: JD
authors: Laughlin
authors: Jeremy
authors: J
authors: Chambers
authors: Mariana
authors: M
authors: Figuera-Losada
authors: Michael D
authors: MD
authors: Cameron
authors: Li
authors: L
authors: Lin
authors: Claudia H
authors: CH
authors: Ruiz
authors: Philip V
authors: PV
authors: LoGrasso
mesh_terms: D000818:Animals; D018360:Crystallography, X-Ray; D015195:Drug Design; D048031:JNK Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors*; D051379:Mice; D008810:Mice, Inbred C57BL; D008958:Models, Molecular; D047428:Protein Kinase Inhibitors / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology*; D011743:Pyrimidines / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D017382:Reactive Oxygen Species / Q000037:antagonists & inhibitors / Q000378:metabolism; D013329:Structure-Activity Relationship
chemical_list: D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D017382:Reactive Oxygen Species; D048031:JNK Mitogen-Activated Protein Kinases